查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2157169

AAV基因治療市場：全球市場預測，2026-2032年

AAV Gene Therapy Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，AAV 基因治療市場將成長至 418.8 億美元，複合年成長率為 22.90%。

主要市場統計數據
基準年 2025 98.8億美元
預計年份：2026年 120.3億美元
預測年份 2032 418.8億美元
複合年成長率 (%) 22.90%

AAV基因療法：概述

腺結合病毒（AAV）基因療法是一種利用基因改造的病毒載體將遺傳物質送至目標細胞的藥物。隨著載體設計、生產、臨床開發和監管科學的進步，該領域正在不斷發展。其主要應用前景在於治療治療選擇有限的嚴重，但其主要局限性包括免疫反應、組織標靶化、持久性、生產過程複雜以及證據要件。

載體科學和遞送技術如何改變這一領域

該領域的研究趨勢正從概念驗證（PoC）療法轉向更精確地控制體內分佈、外源基因表現和重複給藥。研發人員正在研究衣殼修飾、組織特異性啟動子、劑量最佳化、替代給藥途徑以及降低現有免疫反應的方法。生產製造也在不斷發展，包括可擴展的上游和下游製程、改進的分析技術以及在製程變更過程中對產品可比性的更充分考慮。

人工智慧將加速藥物發現、開發和監測。

人工智慧正被用於識別衣殼候選物、建立蛋白質結構模型、預測組織親和性、分析臨床和生產數據以及改進臨床試驗設計。雖然這些工具有助於確定實驗優先順序並及早發現品質趨勢，但它們並不能取代實驗室檢驗、透明的資料集、可重複的方法以及監管審查的必要性。最具持久影響的可能來自於將機器學習與精心整理的生物學數據、穩健的過程控制和專家解讀相結合。

區域趨勢：監管、製造和臨床能力

北美在轉化研究、生物技術製造和先進臨床開發方面擁有強大的實力。歐洲則著重協調一致的監管要求、專業的學術研究中心以及跨境證據的累積。亞太地區擁有不斷擴展的研究基礎設施、龐大的患者群體和日益成長的生產能力。拉丁美洲儘管面臨准入和基礎設施的限制，但仍在努力提升其臨床和監管能力。中東地區正選擇性地投資先進的醫療保健和生物技術平台，而非洲則繼續致力於建構複雜基因療法所需的研發、診斷、生產和轉診體系。

群體觀點：合作與政策協調

東南亞國協雖然監管和基礎設施成熟度不一，但在區域臨床試驗網路、醫療衛生系統發展和技術轉移方面發揮重要作用。金磚國家擁有重要的研究、製造和病患生態系統，其合作受到各國法規和產業政策差異的影響。歐盟受益於協調一致的科學和監管框架，而七國集團則提供具有影響力的標準、研究能力和資金籌措管道。海灣合作理事會國家正在努力加強其專業醫療衛生和生物技術能力。北約成員國擁有眾多先進的生物醫學生態系統，但以國防為導向的合作並不能取代國家法規、報銷政策或臨床管治。

針對特定國家的研究、監管和存取情況進行分析。

美國和加拿大在先進的臨床研究、專業製造和完善的監管體系方面擁有豐富的經驗。英國、法國、德國、義大利和西班牙則透過學術醫學、歐洲監管協調以及對國家醫療保健系統的評估做出貢獻。中國正在擴大其國內創新、臨床基礎設施和製造能力，而日本和韓國則擁有強大的轉化科學和先進的生物製造能力。澳洲透過專門機構和系統化的法規環境支持基因治療研究。印度正在加強其生物技術、臨床研究和製造能力。巴西和墨西哥是拉丁美洲專業醫學和臨床開發的重要中心，而俄羅斯則在監管、資金籌措和國際合作條件允許的情況下，保持其在科學和醫療保健領域的能力。

領導者在建構永續的AAV基因治療計畫方面應優先考慮的事項

產業領導者應優先考慮具有臨床意義的終點指標、透明的自然病程證據，以及與監管機構和保險公司的早期合作。生產策略應在進入關鍵開發階段之前，建立可擴展的製程流程、檢驗的分析方法、供應鏈彈性以及清晰的可比性計劃。計畫還應評估患者既有的免疫系統、肝臟和其他器官的風險、長期追蹤以及患者識別和治療實施的可行性。負責任地使用人工智慧 (AI) 需要有據可查的檢驗、人工監督、網路安全以及防止結果偏差和不可重複輸出的控制措施。與專科醫院、公共機構和病患團體建立合作關係可以改善轉診、知情同意、監測和公平獲取醫療服務。

調查方法：基於證據的AAV藥物現況評估

本執行摘要從科學、臨床、生產、監管、醫療保健系統和地理等角度對腺相關病毒（AAV）基因療法進行了結構化的定性評估。評估內容來自公開的監管文件、同行評審的研究、臨床試驗文件、技術文獻和既定的醫療保健政策資訊來源。區域、群體和國家層級的觀察結果以情境比較而非數值排名的方式呈現。本評估不涉及市場估算和預測、市場佔有率以及未經證實的說法，而是專注於有文獻證據支持的模式。

結論：透過精準和嚴謹推進AAV療法的發展。

AAV基因療法正經歷技術改進和組織知識累積的階段性發展。未來的成功將更取決於標靶化、安全性、持久性、生產製造、證據生成、監管和患者獲取等各個領域的整合執行，而非載體本身的新穎性。那些能夠將嚴謹的轉化科學、穩健的生產系統、負責任的人工智慧和協調的醫療保健系統規劃相結合的機構，將更有能力把前景廣闊的基因治療方法轉化為可靠的臨床應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 AAV基因治療市場：依適應症分類

  • 血液學
    • BETA-地中海型貧血
    • A型血友病A
    • B型血友病
  • 代謝性疾病
    • 法布瑞氏症
    • 高雪氏症
  • 肌肉骨骼系統
    • 貝克氏肌肉萎縮症
    • Duchenne氏肌肉失養症
  • 神經病學
    • 阿茲海默症
    • 帕金森氏症
    • 脊髓性肌肉萎縮症
  • 眼科
    • 老齡化黃斑部病變
    • 萊伯先天性失明
    • 視網膜營養不良

第8章 AAV基因治療市場：依載體類型分類

  • AAV2
  • AAV5
  • AAV8
  • AAV9

第9章：AAV基因治療市場：依最終用戶分類

  • 契約製造組織
  • 醫院
  • 研究機構
  • 專科診所

第10章：AAV基因治療市場：依給藥途徑分類

  • 肌肉內部
  • 鞘內給藥
  • 靜脈
  • 視網膜下

第11章 AAV基因治療市場：依治療階段分類

  • 已通過核准的
  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前階段

第12章：AAV基因治療市場：依治療方式分類

  • 聯合治療
  • 單藥治療

第13章：AAV基因治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 AAV基因治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 AAV基因治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • 4D Molecular Therapeutics
  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio Inc.
  • Capsida Biotherapeutics
  • CRISPR Therapeutics AG
  • CSL Behring LLC
  • F. Hoffmann-La Roche Ltd.
  • Krystal Biotech Inc.
  • MeiraGTx
  • Novartis AG
  • Pfizer Inc.
  • REGENXBIO Inc.
  • Sarepta Therapeutics Inc.
  • Spark Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • uniQure NV
  • Vertex Pharmaceuticals Incorporated
  • Voyager Therapeutics Inc.

第18章 主要專家

Product Code: MRR-EF0BD2D829C3

The AAV Gene Therapy Drugs Market is projected to grow by USD 41.88 billion at a CAGR of 22.90% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.88 billion
Estimated Year [2026] USD 12.03 billion
Forecast Year [2032] USD 41.88 billion
CAGR (%) 22.90%

AAV Gene Therapy Drugs: Executive Overview

Adeno-associated virus (AAV) gene therapy drugs are medicines that use engineered viral vectors to deliver genetic material to target cells. The field is advancing through improved vector design, manufacturing, clinical development, and regulatory science. Its principal opportunities lie in treating serious diseases with limited therapeutic options, while its principal constraints include immune responses, tissue targeting, durability, manufacturing complexity, and high evidentiary requirements.

How Vector Science and Delivery Are Reshaping the Field

The landscape is shifting from proof-of-concept therapies toward more precise control of biodistribution, transgene expression, and repeat dosing. Developers are investigating capsid engineering, tissue-specific promoters, dose optimization, alternative administration routes, and methods to reduce pre-existing immunity. Manufacturing is also evolving through scalable upstream and downstream processes, improved analytics, and greater attention to product comparability when processes change.

Artificial Intelligence Accelerates Discovery, Development, and Oversight

Artificial intelligence is being applied to identify capsid candidates, model protein structure, predict tissue tropism, analyze clinical and manufacturing data, and improve trial design. These tools can help prioritize experiments and detect quality trends earlier, but they do not remove the need for laboratory validation, transparent datasets, reproducible methods, and regulatory review. The most durable impact is likely to come from combining machine learning with curated biological data, robust process controls, and expert interpretation.

Regional Dynamics: Regulation, Manufacturing, and Clinical Capability

North America has strong capabilities in translational research, biotechnology manufacturing, and advanced clinical development. Europe emphasizes harmonized regulatory expectations, specialized academic centers, and cross-border evidence generation. Asia-Pacific combines expanding research infrastructure with substantial patient populations and growing manufacturing capacity. Latin America is developing clinical and regulatory capabilities while facing access and infrastructure constraints. The Middle East is investing selectively in advanced healthcare and biotechnology platforms, whereas Africa remains focused on building research, diagnostic, manufacturing, and referral capacity needed for complex genetic medicines.

Group Perspectives: Cooperation and Policy Alignment

ASEAN countries are relevant to regional trial networks, health-system readiness, and technology transfer, although regulatory and infrastructure maturity varies. BRICS members span major research, manufacturing, and patient ecosystems, with collaboration shaped by differing rules and industrial policies. The European Union benefits from coordinated scientific and regulatory frameworks, while the G7 provides influential standards, research capacity, and financing channels. GCC states are strengthening specialized healthcare and biotechnology capabilities. NATO members collectively include many advanced biomedical ecosystems, but defense alignment does not replace national regulation, reimbursement policy, or clinical governance.

Country Insights Across Research, Regulation, and Access

The United States and Canada combine advanced clinical research, specialized manufacturing, and established regulatory expertise. The United Kingdom, France, Germany, Italy, and Spain contribute through academic medicine, European regulatory coordination, and national health-system assessment. China is expanding domestic innovation, clinical infrastructure, and manufacturing capabilities, while Japan and South Korea bring strong translational science and advanced biomanufacturing. Australia supports gene-therapy research through specialized institutions and a structured regulatory environment. India is strengthening biotechnology, clinical research, and manufacturing capacity. Brazil and Mexico are important Latin American centers for specialist care and clinical development, while Russia retains scientific and healthcare capabilities subject to regulatory, funding, and international collaboration conditions.

Priorities for Leaders Building Durable AAV Gene Therapy Programs

Industry leaders should prioritize clinically meaningful endpoints, transparent natural-history evidence, and early engagement with regulators and payers. Manufacturing strategies should establish scalable processes, validated analytical methods, supply resilience, and clear comparability plans before pivotal development. Programs should also assess pre-existing immunity, liver and other organ risks, long-term follow-up, and the feasibility of patient identification and treatment delivery. Responsible use of artificial intelligence requires documented validation, human oversight, cybersecurity, and controls against biased or irreproducible outputs. Partnerships with specialist hospitals, public agencies, and patient organizations can improve referral, consent, monitoring, and equitable access.

Methodology: Evidence-Based Assessment of the AAV Drug Landscape

This executive summary uses a structured qualitative assessment of AAV gene therapy drugs across scientific, clinical, manufacturing, regulatory, health-system, and geographic dimensions. Insights are derived from publicly available regulatory materials, peer-reviewed research, clinical-trial documentation, technical literature, and established healthcare-policy sources. Regional, group, and country observations are presented as contextual comparisons rather than numerical rankings. The assessment excludes market estimates, market shares, forecasts, and unsupported claims, and emphasizes patterns that can be corroborated through documented evidence.

Conclusion: Advancing AAV Therapies Through Precision and Discipline

AAV gene therapy drugs are progressing through a period of technical refinement and institutional learning. Future success will depend less on vector novelty alone than on integrated execution across targeting, safety, durability, manufacturing, evidence generation, regulation, and patient access. Organizations that pair rigorous translational science with resilient production, responsible artificial intelligence, and coordinated health-system planning will be better positioned to convert promising genetic approaches into dependable clinical care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. AAV Gene Therapy Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Hematology
    • 7.2.1. Beta Thalassemia
    • 7.2.2. Hemophilia A
    • 7.2.3. Hemophilia B
  • 7.3. Metabolic
    • 7.3.1. Fabry Disease
    • 7.3.2. Gaucher Disease
  • 7.4. Musculoskeletal
    • 7.4.1. Becker Muscular Dystrophy
    • 7.4.2. Duchenne Muscular Dystrophy
  • 7.5. Neurology
    • 7.5.1. Alzheimer's Disease
    • 7.5.2. Parkinson's Disease
    • 7.5.3. Spinal Muscular Atrophy
  • 7.6. Ophthalmology
    • 7.6.1. Age Related Macular Degeneration
    • 7.6.2. Leber's Congenital Amaurosis
    • 7.6.3. Retinal Dystrophy

8. AAV Gene Therapy Drugs Market, by Vector Type

  • 8.1. Introduction
  • 8.2. AAV2
  • 8.3. AAV5
  • 8.4. AAV8
  • 8.5. AAV9

9. AAV Gene Therapy Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Contract Manufacturing Organizations
  • 9.3. Hospitals
  • 9.4. Research Institutes
  • 9.5. Specialty Clinics

10. AAV Gene Therapy Drugs Market, by Administration Route

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intrathecal
  • 10.4. Intravenous
  • 10.5. Subretinal

11. AAV Gene Therapy Drugs Market, by Therapy Stage

  • 11.1. Introduction
  • 11.2. Approved
  • 11.3. Phase I
  • 11.4. Phase II
  • 11.5. Phase III
  • 11.6. Preclinical

12. AAV Gene Therapy Drugs Market, by Modality

  • 12.1. Introduction
  • 12.2. Combination Therapy
  • 12.3. Monotherapy

13. AAV Gene Therapy Drugs Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. AAV Gene Therapy Drugs Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. AAV Gene Therapy Drugs Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. 4D Molecular Therapeutics
  • 17.2. Abeona Therapeutics Inc.
  • 17.3. Adaptimmune Therapeutics PLC
  • 17.4. Adverum Biotechnologies Inc.
  • 17.5. Amgen Inc.
  • 17.6. Astellas Pharma Inc.
  • 17.7. BioMarin Pharmaceutical Inc.
  • 17.8. bluebird bio Inc.
  • 17.9. Capsida Biotherapeutics
  • 17.10. CRISPR Therapeutics AG
  • 17.11. CSL Behring LLC
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. Krystal Biotech Inc.
  • 17.14. MeiraGTx
  • 17.15. Novartis AG
  • 17.16. Pfizer Inc.
  • 17.17. REGENXBIO Inc.
  • 17.18. Sarepta Therapeutics Inc.
  • 17.19. Spark Therapeutics Inc.
  • 17.20. Takeda Pharmaceutical Company Limited
  • 17.21. uniQure N.V.
  • 17.22. Vertex Pharmaceuticals Incorporated
  • 17.23. Voyager Therapeutics Inc.

18. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global AAV Gene Therapy Drugs Market, Years Considered for the Study
  • FIGURE 2. Global AAV Gene Therapy Drugs Market, Research Design
  • FIGURE 3. Global AAV Gene Therapy Drugs Market, Research Framework
  • FIGURE 4. Global AAV Gene Therapy Drugs Market, Data Triangulation
  • FIGURE 5. Global AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global AAV Gene Therapy Drugs Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global AAV Gene Therapy Drugs Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global AAV Gene Therapy Drugs Market Size, by Vector Type, 2025 vs 2032 (%)
  • FIGURE 9. Global AAV Gene Therapy Drugs Market Size, by Vector Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global AAV Gene Therapy Drugs Market Size, by End-User, 2025 vs 2032 (%)
  • FIGURE 11. Global AAV Gene Therapy Drugs Market Size, by End-User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global AAV Gene Therapy Drugs Market Size, by Administration Route, 2025 vs 2032 (%)
  • FIGURE 13. Global AAV Gene Therapy Drugs Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2025 vs 2032 (%)
  • FIGURE 15. Global AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global AAV Gene Therapy Drugs Market Size, by Modality, 2025 vs 2032 (%)
  • FIGURE 17. Global AAV Gene Therapy Drugs Market Size, by Modality, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global AAV Gene Therapy Drugs Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global AAV Gene Therapy Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global AAV Gene Therapy Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global AAV Gene Therapy Drugs Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global AAV Gene Therapy Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global AAV Gene Therapy Drugs Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global AAV Gene Therapy Drugs Market Segmentation & Coverage
  • TABLE 2. Global AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Hematology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Hematology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Hematology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Beta Thalassemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Beta Thalassemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Beta Thalassemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Hemophilia A Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Hemophilia A Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Hemophilia A Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Hemophilia B Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Hemophilia B Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Hemophilia B Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Metabolic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Metabolic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Metabolic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Fabry Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Fabry Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Fabry Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Gaucher Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Gaucher Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Gaucher Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Musculoskeletal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Musculoskeletal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Musculoskeletal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Becker Muscular Dystrophy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Becker Muscular Dystrophy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Becker Muscular Dystrophy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Duchenne Muscular Dystrophy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Duchenne Muscular Dystrophy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Duchenne Muscular Dystrophy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Neurology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Neurology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Neurology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Alzheimer's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Alzheimer's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Alzheimer's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Spinal Muscular Atrophy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Spinal Muscular Atrophy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Spinal Muscular Atrophy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Ophthalmology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Ophthalmology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Ophthalmology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Age Related Macular Degeneration Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Age Related Macular Degeneration Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Age Related Macular Degeneration Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Leber's Congenital Amaurosis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 53. Global Leber's Congenital Amaurosis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 54. Global Leber's Congenital Amaurosis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 55. Global Retinal Dystrophy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Retinal Dystrophy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Retinal Dystrophy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 59. Global AAV2 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global AAV2 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global AAV2 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global AAV5 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global AAV5 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global AAV5 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global AAV8 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global AAV8 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global AAV8 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global AAV9 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 69. Global AAV9 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 70. Global AAV9 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 71. Global AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 72. Global Contract Manufacturing Organizations Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Contract Manufacturing Organizations Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Contract Manufacturing Organizations Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 85. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 86. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 87. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 88. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 90. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 91. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 93. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 94. Global Subretinal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 95. Global Subretinal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 96. Global Subretinal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 97. Global AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 98. Global Approved Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Global Approved Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. Global Approved Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 101. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 104. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 107. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 110. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 113. Global AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 114. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 117. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 118. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 120. Global AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 122. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 123. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 124. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 125. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 126. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 127. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 128. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 129. Asia-Pacific AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 130. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 131. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 132. Asia-Pacific AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 133. North America AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 134. North America AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 135. North America AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 136. North America AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 137. North America AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 138. North America AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 139. North America AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 140. North America AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 141. North America AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 142. North America AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 143. North America AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 144. North America AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 145. Latin America AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 146. Latin America AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 147. Latin America AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 148. Latin America AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 149. Latin America AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 150. Latin America AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 151. Latin America AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 152. Latin America AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 153. Latin America AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 154. Latin America AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 155. Latin America AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 156. Latin America AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 157. Europe AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 158. Europe AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 159. Europe AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 160. Europe AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 161. Europe AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 162. Europe AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 163. Europe AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 164. Europe AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 165. Europe AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 166. Europe AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 167. Europe AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 168. Europe AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 169. Middle East AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 170. Middle East AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 171. Middle East AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 172. Middle East AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 173. Middle East AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 174. Middle East AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 175. Middle East AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 176. Middle East AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 177. Middle East AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 178. Middle East AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 179. Middle East AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 180. Middle East AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 181. Africa AAV Gene Therapy Drugs Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 182. Africa AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 183. Africa AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 184. Africa AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 185. Africa AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 186. Africa AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 187. Africa AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 188. Africa AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 189. Africa AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 190. Africa AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 191. Africa AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 192. Africa AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 193. Global AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 194. ASEAN AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 195. ASEAN AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 196. ASEAN AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 197. ASEAN AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 198. ASEAN AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 199. ASEAN AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 200. ASEAN AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 201. ASEAN AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 202. ASEAN AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 203. ASEAN AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 204. ASEAN AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 205. ASEAN AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 206. GCC AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 207. GCC AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 208. GCC AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 209. GCC AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 210. GCC AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 211. GCC AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 212. GCC AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 213. GCC AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 214. GCC AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 215. GCC AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 216. GCC AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 217. GCC AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 218. European Union AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 219. European Union AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 220. European Union AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 221. European Union AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 222. European Union AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 223. European Union AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 224. European Union AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 225. European Union AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 226. European Union AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 227. European Union AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 228. European Union AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 229. European Union AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 230. BRICS AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 231. BRICS AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 232. BRICS AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 233. BRICS AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 234. BRICS AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 235. BRICS AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 236. BRICS AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 237. BRICS AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 238. BRICS AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 239. BRICS AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 240. BRICS AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 241. BRICS AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 242. G7 AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 243. G7 AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 244. G7 AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 245. G7 AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 246. G7 AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 247. G7 AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 248. G7 AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 249. G7 AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 250. G7 AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 251. G7 AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 252. G7 AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 253. G7 AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 254. NATO AAV Gene Therapy Drugs Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 255. NATO AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 256. NATO AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 257. NATO AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 258. NATO AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 259. NATO AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 260. NATO AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 261. NATO AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 262. NATO AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 263. NATO AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 264. NATO AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 265. NATO AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 266. Global AAV Gene Therapy Drugs Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 267. United States AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 268. United States AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 269. United States AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 270. United States AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 271. United States AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 272. United States AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 273. United States AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 274. United States AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 275. United States AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 276. United States AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 277. United States AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 278. United States AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 279. Canada AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 280. Canada AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 281. Canada AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 282. Canada AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 283. Canada AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 284. Canada AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 285. Canada AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 286. Canada AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 287. Canada AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 288. Canada AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 289. Canada AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 290. Canada AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 291. Mexico AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 292. Mexico AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 293. Mexico AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 294. Mexico AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 295. Mexico AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 296. Mexico AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 297. Mexico AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 298. Mexico AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 299. Mexico AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 300. Mexico AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 301. Mexico AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 302. Mexico AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 303. Brazil AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 304. Brazil AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 305. Brazil AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 306. Brazil AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 307. Brazil AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 308. Brazil AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 309. Brazil AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 310. Brazil AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 311. Brazil AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 312. Brazil AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 313. Brazil AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 314. Brazil AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 315. United Kingdom AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 316. United Kingdom AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 317. United Kingdom AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 318. United Kingdom AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 319. United Kingdom AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 320. United Kingdom AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 321. United Kingdom AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 322. United Kingdom AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 323. United Kingdom AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 324. United Kingdom AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 325. United Kingdom AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 326. United Kingdom AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 327. Germany AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 328. Germany AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 329. Germany AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 330. Germany AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 331. Germany AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 332. Germany AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 333. Germany AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 334. Germany AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 335. Germany AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 336. Germany AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 337. Germany AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 338. Germany AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 339. France AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 340. France AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 341. France AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 342. France AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 343. France AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 344. France AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 345. France AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 346. France AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 347. France AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 348. France AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 349. France AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 350. France AAV Gene Therapy Drugs Market Size, by Modality, 2017-2032 (USD Million)
  • TABLE 351. Russia AAV Gene Therapy Drugs Market Size, 2017-2032 (USD Million)
  • TABLE 352. Russia AAV Gene Therapy Drugs Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 353. Russia AAV Gene Therapy Drugs Market Size, by Hematology, 2017-2032 (USD Million)
  • TABLE 354. Russia AAV Gene Therapy Drugs Market Size, by Metabolic, 2017-2032 (USD Million)
  • TABLE 355. Russia AAV Gene Therapy Drugs Market Size, by Musculoskeletal, 2017-2032 (USD Million)
  • TABLE 356. Russia AAV Gene Therapy Drugs Market Size, by Neurology, 2017-2032 (USD Million)
  • TABLE 357. Russia AAV Gene Therapy Drugs Market Size, by Ophthalmology, 2017-2032 (USD Million)
  • TABLE 358. Russia AAV Gene Therapy Drugs Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 359. Russia AAV Gene Therapy Drugs Market Size, by End-User, 2017-2032 (USD Million)
  • TABLE 360. Russia AAV Gene Therapy Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
  • TABLE 361. Russia AAV Gene Therapy Drugs Market Size, by Therapy Stage, 2017-2032 (USD Million)
  • TABLE 362. Russia AAV Gene Therap